
MAIA Biotechnology, Inc.: quarterly results
Price
$1.11
November 20, 2026Market cap $67M
What Ploutos Investor adds for MAIA Biotechnology
Part of Ploutos Investor, €9.99 a month
- The full history: 4 fiscal years, from 2022
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Results, quarter by quarter
When the company put out each quarter's results (its 8-K, item 2.02), what they showed against the same quarter a year before, and how the stock moved on the first session after.
The first session after results
±3.4%average move, either way
1 times upof the last 43 times down
Largest: -6.7% on May 8, 2023 (May 8, 2023).
How the stock moved after each release
The close of the first session after the results against the close before them.
MAIA that sessionS&P 500 the same day
Every release
Revenue and diluted EPS of the quarter reported, with the change against the same quarter a year before.
- –Stock, next session+4.2%
- –Stock, next session+0.0%
- –Stock, next session-6.7%
- –Stock, next session-2.8%
| Quarter | Released | Revenue | EPS | Stock, next session | S&P 500 | Filing |
|---|---|---|---|---|---|---|
| – | Nov 7, 2023before the close | – | – | +4.2% | +0.3% | 8-K |
| – | Aug 8, 2023before the close | – | – | +0.0% | -0.4% | 8-K |
| – | May 8, 2023before the close | – | – | -6.7% | +0.0% | 8-K |
| – | Mar 24, 2023after the close | – | – | -2.8% | +0.2% | 8-K |
Every release
MAIA's results days and the share's move after each, from Q3 2022 to Q4 2022, 2 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 6 quarters.
Times are the SEC's acceptance of the 8-K, in New York time: before 16:00 the market traded on it that day, after it the next day. A move on a results day has other causes too, and says nothing about the next one. A dash in a quarter's figures: the SEC's structured data does not have them.
The full analysis
What do MAIA Biotechnology's filings show?
The results say what MAIA Biotechnology reported. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.